XSHE
300357
Market cap1.55bUSD
Oct 09, Last price
19.99CNY
1D
1.06%
1Q
-15.40%
Jan 2017
-42.92%
IPO
-61.86%
Name
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd
Chart & performance
P/E
27.48
P/S
9.85
EPS
0.73
Div yield, %
1.11%
Shrs. gr., 5y
—
Rev. gr., 5y
10.80%
Revenues
1.06b
+14.81%
Net income
381m
+19.86%
CFO
423m
+61.25%
Dividend
Jul 09, 20260.15 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. operates as a biopharmaceutical enterprise, primarily engaged in the discovery, development, production, and sale of medicinal products. The company's core focus is on pharmaceuticals designed for the diagnosis and management of allergic conditions, which it supplies to both the Chinese domestic market and international clientele. Additionally, its portfolio encompasses various skincare lines and stem cell-related solutions. The firm's main offices are located in Huzhou, China.
Key people
Guoqi Wang
Finance Director · since 2022
Jianming He
General Manager · since 2024
Ziqiang Bi
Deputy General Manager, Director · since 2016
Mushuang Hu
Deputy General Manager · since 2025
Gengxi Hu
Executive Chairman of the Board · since 2025
Zhenwei Guan
Deputy General Manager, Secretary of the Board · since 2020
Yanni Chen
Director · since 2011
Long Ji
Staff Elected Director · since 2025
Baojie Li
Independent Director · since 2025
Feida Zhang
Independent Director · since 2022
Headquarters & legal address
浙江省德清县武康镇志远北路636号
湖州市, ZJ 310000
CN
湖州市, ZJ 310000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||